New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
15:09 EDTHIG, EW, YUM, LIFE, GILD, TMK, LEG, APCCompanies reporting After the Market Close on Monday, February 4
Notable companies reporting after the bell include Anadarko Petroleum (APC), Gilead Sciences (GILD), Edwards Lifesciences (EW), Leggett & Platt (LEG), Life Technologies (LIFE), The Hartford Financial Services Group (HIG), Torchmark (TMK) and Yum! Brands (YUM).
News For APC;GILD;EW;LEG;LIFE;HIG;TMK;YUM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 26, 2015
10:46 EDTGILDAnthem sued for denying coverage for Gilead's Harvoni, WSJ says
Subscribe for More Information
May 22, 2015
16:28 EDTLIFEPolaris Venture Partners reports 8.2% stake in aTyr Pharma
Subscribe for More Information
16:00 EDTGILDOptions Update; May 22, 2015
Subscribe for More Information
10:34 EDTYUMYum! Brands management to meet with Oppenheimer
Subscribe for More Information
May 21, 2015
10:58 EDTGILDDeutsche Bank biotech analyst holds an analyst/industry conference call
Subscribe for More Information
07:16 EDTLEGLongbow to hold a conference
Subscribe for More Information
May 20, 2015
09:07 EDTGILDGilead's patent for Hep C drug sofosbuvir challenged by NGO's in five countries
Subscribe for More Information
07:26 EDTAPCUBS to hold a conference
Subscribe for More Information
05:30 EDTEWEdwards Lifesciences announces outcomes for patients treated with SAPIEN 3 valve
Edwards Lifesciences announced that 30-day outcomes for intermediate-risk patients treated transfemorally with the SAPIEN 3 transcatheter aortic valve at centers in Europe and Canada demonstrated very low mortality and stroke rates, and no severe paravalvular leaks. These independently adjudicated data are consistent with the outcomes recently reported in a similar study of 1,000 patients treated at 51 centers in the United States. In the multi-center study of 101 intermediate-risk patients, all-cause mortality was 1 percent. The frequency of other important complications was also low: the disabling stroke rate was 2 percent, major vascular complications were 2 percent and the permanent pacemaker rate was 4 percent. The investigators also noted that the SAPIEN 3 valve had excellent hemodynamic performance, with very low incidence of significant paravalvular regurgitation, as only 2.3 percent of patients had moderate paravalvular leaks and there were no reports of severe leaks.
May 19, 2015
10:09 EDTGILDGilead CFO says 'really excited' about options to grow beyond 2018
Subscribe for More Information
09:21 EDTEWEdwards Lifesciences voluntarily pauses enrollment for Fortis clinical program
Subscribe for More Information
08:48 EDTEWEdwards Lifesciences reports positive results from treatment with SAPIEN 3
Subscribe for More Information
07:56 EDTGILDGilead for Achillion rumor not ridiculous, but highly unlikely, TheStreet says
Subscribe for More Information
07:28 EDTGILDUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link
May 18, 2015
19:43 EDTGILDAnthem Blue Cross sued for limiting Harvoni usage, LA Times says
Subscribe for More Information
16:16 EDTGILDGilead confirms plans to present tomorrow at UBS conference, Feuerstein reports
Subscribe for More Information
14:42 EDTGILDAchillion rises as conference cancellation adds fuel to M&A speculation
Subscribe for More Information
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
08:35 EDTYUMYum! Brands price target raised to $105 from $90 at Oppenheimer
Subscribe for More Information
05:10 EDTAPCAnadarko selects contractor for initial onshore Mozambique LNG development
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use